Minhua Chu: BNT327 (Pumitamig) Shows Promising Efficacy in ES-SCLC in Phase II Trial
Minhua Chu, Managing Partner at TransitionValue Partner, shared on X:
“The abstract of BNT327 (pumitamig) submitted by $BNTX to WCLC2025 has been published.
In a randomized, open-label, global Phase II clinical trial (NCT06449209), as of April 4, 2025, Cohort 1 enrolled 43 patients with treatment-naïve ES-SCLC.
22 patients received 20 mg/kg BNT327 every 3 weeks, and 21 patients received 30 mg/kg BNT327 every 3 weeks.
Patients underwent 4 cycles of BNT327 combined with etoposide and carboplatin, followed by BNT327 maintenance therapy.
Among the 38 patients evaluable for efficacy,
uORR was 86.8% (33/38, all partial responses), with the remaining 5 patients achieving stable disease (SD), DCR was 100%.
The ORR in the 20 mg/kg and 30 mg/kg dose groups was 95.0% and 77.8%, respectively.
BNT327 (pumitamig) is a PD-L1/VEGF-A bispecific antibody developed by 🇨🇳 Biotheus.
In Nov 2023, BioNTech entered into a strategic collaboration with Biotheus, securing global (excluding Greater China) rights for the drug.
One year later, BioNTech acquired Biotheus for $950 million.
In Jun this year, $BMY securing global co-development and commercialization rights for BNT327.”
More posts featuring Minhua Chu.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023